A new study reveals a novel connection between aging of visceral adipose tissue and brain health. These findings are ...

CereVasc, Inc., a clinical-stage medical device company developing novel treatments for neurological diseases, announced ...

A New Drug Application has been accepted seeking accelerated approval for dordaviprone for patients with recurrent H3 ...

We present a case report of a large recurrent incisional hernia following multiple prior procedures. The patient underwent a tension-free hernia repair using the hernia sac as a peritoneal flap. The ...

NXP800 Phase 1b study in patients with platinum resistant, ARID1a-mutated ovarian cancer is ongoing; Orphan Drug Designation ...

CereVasc today announced the first patient randomized to and treated with the eShunt system in its STRIDE clinical trial.

Ron Bentsur, CEO commented, “In 2024, Nuvectis made important progress in the development of our two clinical-stage drug candidates, NXP800 and ...

CEBU CITY, Cebu (PIA) –The Philippine Health Insurance Corporation (PhilHealth) has substantially enhanced its Z Benefit Package for Peritoneal Dialysis (PD) up to 1.2M starting January 2025. The ...

QUEZON CITY, (PIA) — In line with President Ferdinand R. Marcos Jr.’s commitment to expanding healthcare benefits, the Philippine Health Insurance Corporation (PhilHealth) has significantly enhanced ...